150 related articles for article (PubMed ID: 20406091)
1. Translational therapies for malignant pleural mesothelioma.
Belli C; Anand S; Tassi G; Fennell D; Mutti L
Expert Rev Respir Med; 2010 Apr; 4(2):249-60. PubMed ID: 20406091
[TBL] [Abstract][Full Text] [Related]
2. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
3. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal V; Lind MJ; Cawkwell L
Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
[TBL] [Abstract][Full Text] [Related]
4. Biology and management of malignant pleural mesothelioma.
Zucali PA; Giaccone G
Eur J Cancer; 2006 Nov; 42(16):2706-14. PubMed ID: 16989994
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
Greillier L; Marco S; Barlesi F
Anticancer Drugs; 2011 Mar; 22(3):199-205. PubMed ID: 21263312
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
7. Review on clinical trials of targeted treatments in malignant mesothelioma.
Jakobsen JN; Sørensen JB
Cancer Chemother Pharmacol; 2011 Jul; 68(1):1-15. PubMed ID: 21553148
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets in malignant pleural mesothelioma treatment.
Pasello G; Favaretto A
Curr Drug Targets; 2009 Dec; 10(12):1235-44. PubMed ID: 19909234
[TBL] [Abstract][Full Text] [Related]
9. Advances in the biology of malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
11. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
12. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Kindler HL
Lung Cancer; 2004 Aug; 45 Suppl 1():S125-7. PubMed ID: 15261445
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
Motadi LR; Misso NL; Dlamini Z; Bhoola KD
Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: current treatments and emerging drugs.
Belli C; Fennell D; Giovannini M; Gaudino G; Mutti L
Expert Opin Emerg Drugs; 2009 Sep; 14(3):423-37. PubMed ID: 19552609
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma: medical treatment update.
Vorobiof DA; Mafafo K
Clin Lung Cancer; 2009 Mar; 10(2):112-7. PubMed ID: 19362954
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.
Kai K; D'Costa S; Sills RC; Kim Y
Cancer Lett; 2009 Jun; 278(1):49-55. PubMed ID: 19178995
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
